Food and Drug Administration

At the Food and Drug Administration (FDA), Vergys provided subject matter expertise to the existing contractor and government-led capital planning and investment control team. In that capacity, our team delivered an executive training session on PortfolioStat and the Exhibit 300. We provided guidance on the usage of baseline change events and best practices for earned value management reporting. We also suggested updates to the business case metrics across the relevant segments of the FDA portfolio.